VivoSeq
Other

NSCLC Stage IV

3

Pipeline Programs↗

3

Active Trials↗

3

Companies Involved↗

NSCLC Stage IV is an early-stage landscape with 3 programs across 3 companies. The most active players are Karuna Therapeutics, Inc., a Bristol Myers Squibb company, Regeneron, Eli Lilly.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

N/A

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

K

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

2 programs

Phase 2Regeneron logo

Regeneron

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2

Pipeline

Programs by Phase

Analysis

Modality Breakdown

67%

Small molecule

2 of 3 classified programs — the dominant modality here.

33%ALL OTHERSMonoclonal antibody133%

Small molecule leads; the ring shows all 3 classified programs, each share of the total. Modality classified for 75% of 4 pipeline programs.

Analysis

Trial Status

3

clinical trials

Active, not recruiting2 · 67%
Recruiting1 · 33%

Clinical Trials

Trial Activity

Open-label Phase II Efficacy Study of Repotrectinib in Frail (PS ≥2) and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
Recruiting·CCentre Hospitalier Intercommunal de Toulon La Seyne sur Mer·Phase 2·NCT06552234·30 enrolled
Immunotherapy Consolidation After Radical Treatment of Synchronous Oligo-metastatic NSCLC
Active, not recruiting·EEuropean Organisation for Research and Treatment of Cancer - EORTC·Phase 2·NCT06219317·136 enrolled
A Multicentre, Single-arm Phase II Trial of Adagrasib in Patients With KRASG12C-mutant NSCLC, Including the Elderly (≥70 Years) or Patients With Poor Performance Status
Active, not recruiting·EETOP IBCSG Partners Foundation·Phase 2·NCT05673187·68 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)